10/17/2023
Discontinuation of API Ingredients on the FDA Category 2 List
October 16, 2023
Dear Esteemed Practices and Prescribers,
We deeply value the ongoing relationship we share with you and the invaluable role you play in the healthcare community. Today, we must share some unfortunate news regarding certain peptide products that have been integral to many wellness practices and patients' lives.
Recently, select peptide products have been added to the FDA Category 2 list. We understand the profound impact these medications have had on patients with various ailments, especially those for whom traditional medications offered limited relief.
It is with a heavy heart that we announce the discontinuation of the following API ingredients and their respective compounded products within the next 30 days:
1) CJC-1295
2) Ipamorelin
3) BPC 157
4) Ibutamoren
5) AOD 9604
6) Kisspeptin
To assist practitioners in making necessary prescription arrangements and preparing for therapeutic transitions, we are granting a 30-day grace period or until inventory depletion, whichever comes first. Rest assured, we will keep you informed of any inventory that may have been exhausted prior to this notice.
Furthermore, please be advised that orders containing prescriptions comprising any of the aforementioned active pharmaceutical ingredients will be automatically canceled after 30 days from the issuance of this notice.
We recognize that these medications have been life-changing for many, and we share in the disappointment of losing such valuable treatment options. The wellness practices and patients who have benefited from these products have experienced remarkable improvements in their quality of life, and we are acutely aware of the challenges they may face in finding suitable alternatives.
However, please rest assured that we are committed to assisting you during this transition period. While we acknowledge that there may be limited alternatives that can match the effectiveness of these peptide products, we are here to support you in exploring other treatment options that may benefit your patients.
Our dedicated team will work closely with you to identify alternative medications, therapies, or approaches that may be suitable for your patients' specific needs.
Thank you for your understanding and continued partnership. We look forward to supporting you during this transition and in all your future endeavors in healthcare.
Sincerely,
Hallandale Pharmacy Compliance Department
